NLS Pharmaceutics Aktie
| 2,26USD | -0,04USD | -1,74% |
ISIN: CH1384053976
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 4 | 6 | 6 | 2 | 4 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 0 | 0 | 6 | 9 | 2 |
| Summe Anlagevermögen | 0 | 1 | 0 | 0 | 0 |
| Summe Aktiva | 1 | 1 | 6 | 9 | 2 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 7 | 10 | 5 | 6 | 11 |
| Summe Eigenkapital | -6 | -9 | 1 | 3 | -9 |
| Summe Passiva | 1 | 1 | 6 | 9 | 2 |
Adresse
| The Circle 6, 8058 Zurich | |
| Telefon | +41 (44) 512-21-50 |
| Internet | http://www.nlspharma.com |
Management
|
Alexander C. Zwyer
Chief Executive Officer & Director |
|
Audrey E. Greenberg
Independent Director |
|
Claudio L. A. Bassetti
Independent Director |
|
Eric Konofal
Chief Scientific Officer |
|
Florence Allouche Aknin
Independent Director |
|
George Apostol
Chief Medical Officer & Head-Global Research |
|
Gian-Marco Rinaldi Diaz de la Cruz
Independent Director |
|
Hervé Girsault
Head-Business Development |
|
Marianne Lambertson
Investor Relations & Media Contact |
|
Nicole Fernandez-McGovern
Chief Operating & Financial Officer |
|
Ronald Hafner
Chairman |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.